abbv-20240403

0001551152-24-000013.txt : 20240403 0001551152-24-000013.hdr.sgml : 20240403 20240403160609 ACCESSION NUMBER: 0001551152-24-000013 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240403 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24818707 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20240403.htm 8-K abbv-20240403

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 3, 2024

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35565

32-0375147

(State or other Jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

Identification No.)

_____________________________________________________

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 Par Value

ABBV

New York Stock Exchange

Chicago Stock Exchange

1.375% Senior Notes due 2024

ABBV24

New York Stock Exchange

1.250% Senior Notes due 2024

ABBV24B

New York Stock Exchange

0.750% Senior Notes due 2027

ABBV27

New York Stock Exchange

2.125% Senior Notes due 2028

ABBV28

New York Stock Exchange

2.625% Senior Notes due 2028

ABBV28B

New York Stock Exchange

2.125% Senior Notes due 2029

ABBV29

New York Stock Exchange

1.250% Senior Notes due 2031

ABBV31

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2024 are expected to include acquired IPR&D and milestones expense of $164 million on a pre-tax basis, representing an unfavorable impact of $0.08 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on February 12, 2024 excluded the impact of acquired IPR&D and milestones expense that may be incurred in 2024. AbbVie’s full-year 2024 adjusted diluted earnings per share guidance range, including the impact of first quarter 2024 acquired IPR&D and milestones expense, is $10.97 - $11.17. AbbVie’s first quarter 2024 adjusted diluted earnings per share guidance range, including the impact of first quarter 2024 acquired IPR&D and milestones expense, is $2.18 - $2.22.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2024 including the estimated acquired IPR&D and milestones expense incurred during the first quarter of 2024.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

Forward-Looking Statements

Some statements in this Current Report on Form 8-K are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


Exhibit No.						Exhibit
99.1						Guidance including the impact of acquired IPR&D and milestones expense.
104						The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			ABBVIE INC.

Date:	April 3, 2024	By:	/s/ Scott T. Reents
			Scott T. Reents
			Executive Vice President,
			Chief Financial Officer

EX-99.1 2 abbv-20240331nonxgaapxex991.htm EX-99.1 Document

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)


(in millions, except per share data)	Quarter Ended March 31, 2024						Full-Year Ended December 31, 2024
	Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range				Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range
			Low		High				Low		High
Previously announced guidance excluding Q1 2024 acquired IPR&D and milestones expense	$	—	$	2.26	$	2.30	$	—	$	11.05	$	11.25
Q1 2024 acquired IPR&D and milestones expense	164		(0.08)		(0.08)		164		(0.08)		(0.08)
Guidance including Q1 2024 acquired IPR&D and milestones expensea	$	164	$	2.18	$	2.22	$	164	$	10.97	$	11.17

a The Company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2024, as both cannot be reliably forecasted.

EX-101.SCH 3 abbv-20240403.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 abbv-20240403_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 abbv-20240403_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Sec 2.125 Senior Notes Due 2029 Sec 2.125 Senior Notes Due 2029 [Member] Sec 2.125 Senior Notes Due 2029 Sec 1.375 Senior Notes Due 2024 Sec 1.375 Senior Notes Due 2024 [Member] Sec 1.375 Senior Notes Due 2024 [Member] Exchange [Domain] Exchange [Domain] Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Common Stock Common Stock [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Entity Address, City or Town Entity Address, City or Town Sec 1.250 Senior Notes Due 2024 Sec 1.250 Senior Notes Due 2024 [Member] Sec 1.250 Senior Notes Due 2024 Sec 0.750 Senior Notes Due 2027 Sec 0.750 Senior Notes Due 2027 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Sec 1.250 Senior Notes due 2031 Sec 1.250 Senior Notes due 2031 [Member] Sec 1.250 Senior Notes due 2031 [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Sec 2.125 Senior Notes due 2028 Sec 2.125 Senior Notes due 2028 [Member] Sec 2.125 Senior Notes due 2028 [Member] Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Document Type Document Type Amendment Flag Amendment Flag CHICAGO STOCK EXCHANGE, INC NYSE CHICAGO, INC. [Member] Class of Stock [Axis] Class of Stock [Axis] Entity File Number Entity File Number Sec 2.625 Senior Notes Due 2028 Sec 2.625 Senior Notes Due 2028 [Member] Sec 2.625 Senior Notes Due 2028 Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 abbv-20240403_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information Document	Apr. 03, 2024
Entity Information [Line Items]
Document Type	8-K
Document Period End Date	Apr. 03, 2024
Entity Registrant Name	ABBVIE INC.
Entity Central Index Key	0001551152
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity File Number	001-35565
Entity Tax Identification Number	32-0375147
Entity Address, Address Line One	1 North Waukegan Road
Entity Address, City or Town	North Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	847
Local Phone Number	932-7900
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $0.01 Par Value
Trading Symbol	ABBV
Security Exchange Name	NYSE
Common Stock \| CHICAGO STOCK EXCHANGE, INC
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $0.01 Par Value
Trading Symbol	ABBV
Security Exchange Name	CHX
Sec 1.375 Senior Notes Due 2024 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.375% Senior Notes due 2024
Trading Symbol	ABBV24
Security Exchange Name	NYSE
Sec 1.250 Senior Notes Due 2024 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.250% Senior Notes due 2024
Trading Symbol	ABBV24B
Security Exchange Name	NYSE
Sec 0.750 Senior Notes Due 2027 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.750% Senior Notes due 2027
Trading Symbol	ABBV27
Security Exchange Name	NYSE
Sec 2.125 Senior Notes due 2028 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	2.125% Senior Notes due 2028
Trading Symbol	ABBV28
Security Exchange Name	NYSE
Sec 2.625 Senior Notes Due 2028 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	2.625% Senior Notes due 2028
Trading Symbol	ABBV28B
Security Exchange Name	NYSE
Sec 2.125 Senior Notes Due 2029 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	2.125% Senior Notes due 2029
Trading Symbol	ABBV29
Security Exchange Name	NYSE
Sec 1.250 Senior Notes due 2031 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.250% Senior Notes due 2031
Trading Symbol	ABBV31
Security Exchange Name	NYSE

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 10 22 1 false 10 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://www.abbvie.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports abbv-20240403.htm abbv-20240403.xsd abbv-20240403_def.xml abbv-20240403_lab.xml abbv-20240403_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "abbv-20240403.htm": { "nsprefix": "abbv", "nsuri": "http://www.abbvie.com/20240403", "dts": { "inline": { "local": [ "abbv-20240403.htm" ] }, "schema": { "local": [ "abbv-20240403.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd" ] }, "definitionLink": { "local": [ "abbv-20240403_def.xml" ] }, "labelLink": { "local": [ "abbv-20240403_lab.xml" ] }, "presentationLink": { "local": [ "abbv-20240403_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 2, "axisCustom": 0, "memberStandard": 3, "memberCustom": 7, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 10, "entityCount": 1, "segmentCount": 10, "elementCount": 39, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 46 }, "report": { "R1": { "role": "http://www.abbvie.com/role/DocumentandEntityInformationDocument", "longName": "0000001 - Document - Document and Entity Information Document", "shortName": "Document and Entity Information Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "abbv-20240403.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "abbv-20240403.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExchangeDomain", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "abbv_Sec0.750SeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbvie.com/20240403", "localname": "Sec0.750SeniorNotesDue2027Member", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Sec 0.750 Senior Notes Due 2027", "label": "Sec 0.750 Senior Notes Due 2027 [Member]", "documentation": "Sec 0.750 Senior Notes Due 2027 [Member]" } } }, "auth_ref": [] }, "abbv_Sec1.250SeniorNotesdue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbvie.com/20240403", "localname": "Sec1.250SeniorNotesdue2031Member", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Sec 1.250 Senior Notes due 2031", "label": "Sec 1.250 Senior Notes due 2031 [Member]", "documentation": "Sec 1.250 Senior Notes due 2031 [Member]" } } }, "auth_ref": [] }, "abbv_Sec1.375SeniorNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbvie.com/20240403", "localname": "Sec1.375SeniorNotesDue2024Member", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Sec 1.375 Senior Notes Due 2024", "label": "Sec 1.375 Senior Notes Due 2024 [Member]", "documentation": "Sec 1.375 Senior Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "abbv_Sec1250SeniorNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbvie.com/20240403", "localname": "Sec1250SeniorNotesDue2024Member", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Sec 1.250 Senior Notes Due 2024", "label": "Sec 1.250 Senior Notes Due 2024 [Member]", "documentation": "Sec 1.250 Senior Notes Due 2024" } } }, "auth_ref": [] }, "abbv_Sec2.125SeniorNotesdue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbvie.com/20240403", "localname": "Sec2.125SeniorNotesdue2028Member", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Sec 2.125 Senior Notes due 2028", "label": "Sec 2.125 Senior Notes due 2028 [Member]", "documentation": "Sec 2.125 Senior Notes due 2028 [Member]" } } }, "auth_ref": [] }, "abbv_Sec2125SeniorNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbvie.com/20240403", "localname": "Sec2125SeniorNotesDue2029Member", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Sec 2.125 Senior Notes Due 2029", "label": "Sec 2.125 Senior Notes Due 2029 [Member]", "documentation": "Sec 2.125 Senior Notes Due 2029" } } }, "auth_ref": [] }, "abbv_Sec2625SeniorNotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbvie.com/20240403", "localname": "Sec2625SeniorNotesDue2028Member", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Sec 2.625 Senior Notes Due 2028", "label": "Sec 2.625 Senior Notes Due 2028 [Member]", "documentation": "Sec 2.625 Senior Notes Due 2028" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "exch_XCHI": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2023", "localname": "XCHI", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "CHICAGO STOCK EXCHANGE, INC", "label": "NYSE CHICAGO, INC. [Member]" } } }, "auth_ref": [] }, "exch_XNYS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2023", "localname": "XNYS", "presentation": [ "http://www.abbvie.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "NEW YORK STOCK EXCHANGE, INC.", "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001551152-24-000013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001551152-24-000013-xbrl.zip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end XML 18 abbv-20240403_htm.xml IDEA: XBRL DOCUMENT 0001551152 2024-04-03 2024-04-03 0001551152 us-gaap:CommonStockMember exch:XCHI 2024-04-03 2024-04-03 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-04-03 2024-04-03 0001551152 abbv:Sec1.375SeniorNotesDue2024Member exch:XNYS 2024-04-03 2024-04-03 0001551152 abbv:Sec1250SeniorNotesDue2024Member exch:XNYS 2024-04-03 2024-04-03 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2024-04-03 2024-04-03 0001551152 abbv:Sec2.125SeniorNotesdue2028Member exch:XNYS 2024-04-03 2024-04-03 0001551152 abbv:Sec2625SeniorNotesDue2028Member exch:XNYS 2024-04-03 2024-04-03 0001551152 abbv:Sec2125SeniorNotesDue2029Member exch:XNYS 2024-04-03 2024-04-03 0001551152 abbv:Sec1.250SeniorNotesdue2031Member exch:XNYS 2024-04-03 2024-04-03 0001551152 false 8-K 2024-04-03 ABBVIE INC. DE 001-35565 32-0375147 1 North Waukegan Road North Chicago IL 60064-6400 847 932-7900 false false false false Common Stock, $0.01 Par Value Common Stock, $0.01 Par Value ABBV ABBV NYSE CHX 1.375% Senior Notes due 2024 ABBV24 NYSE 1.250% Senior Notes due 2024 ABBV24B NYSE 0.750% Senior Notes due 2027 ABBV27 NYSE 2.125% Senior Notes due 2028 ABBV28 NYSE 2.625% Senior Notes due 2028 ABBV28B NYSE 2.125% Senior Notes due 2029 ABBV29 NYSE 1.250% Senior Notes due 2031 ABBV31 NYSE false